Howard M. Sandler MD, MS, FASTRORonald H. Bloom Family Chair in Cancer Therapeutics and Professor and Chairman of Radiation Oncology, Samuel Oschin Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California
Dr. Sandler is the Ronald H. Bloom Family Chair in Cancer Therapeutics and Professor and Chairman of Radiation Oncology at the Samuel Oschin Cancer Institute, Cedars-Sinai Medical Center, Los Angeles. He received his undergraduate degree, masters in Physics and medical degree from the University of Connecticut and completed his training in Radiation Oncology at the University of Pennsylvania. He was recruited to Cedars-Sinai in 2008 from the University of Michigan’s National Cancer Institute-designated Comprehensive Cancer Center, where he served as Newman Family Professor of Radiation Oncology.
Dr. Sandler’s research interests include prostate and other genitourinary tumors, as well as a broad range of subjects related to radiation oncology. He has received a number of grants from the National Institutes of Health and other major agencies to conduct research in these areas, and is a leader in developing technology that allows radiation beams to target prostate cancer tumors with greater accuracy and fewer side effects. As chairman of the Radiation Therapy Oncology Group -- now part of NRG Oncology -- Genitourinary Cancer Committee since 1997, he’s led or shaped a number of practice-changing national clinical trials. He has written more than 250 peer-reviewed publications primarily on prostate cancer and radiation therapy.
Recent Contributions to PracticeUpdate:
- Ultra-Hypofractionated Versus Conventionally Fractionated Radiotherapy for Prostate Cancer
- New Concepts in Metastatic Prostate Cancer
- Optimal Duration of Hormone Therapy With Radiation for Localized Prostate Cancer
- Possible Radiotherapy Link With MDS/AML in Patients With Prostate Cancer
- Hormone Therapy After Salvage Radiation in the Post-Prostatectomy Setting
- Radiation Therapy and Hypofractionation Schedules in Prostate Cancer
- ADT Alone vs ADT With Radiotherapy for Prostate Cancer Treatment